152 related articles for article (PubMed ID: 3149736)
1. The protein binding of phenytoin, propranolol, diazepam, and AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum.
McNamara PJ; Blouin RA; Brazzell RK
Pharm Res; 1988 May; 5(5):261-5. PubMed ID: 3149736
[TBL] [Abstract][Full Text] [Related]
2. Serum protein binding of AL01576, a new aldose reductase inhibitor.
McNamara PJ; Blouin RA; Brazzell RK
Pharm Res; 1988 May; 5(5):319-21. PubMed ID: 3149737
[No Abstract] [Full Text] [Related]
3. Altered drug-serum protein binding in the genetically obese Zucker rat.
Benedek IH; Blouin RA; McNamara PJ
J Pharm Sci; 1985 Aug; 74(8):837-40. PubMed ID: 4032266
[TBL] [Abstract][Full Text] [Related]
4. Disposition of the aldose reductase inhibitor AL01576 in rats.
Park YH; Wooldridge CB; Mattern J; Stoltz ML; Brazzell RK
J Pharm Sci; 1988 Feb; 77(2):110-5. PubMed ID: 3129545
[TBL] [Abstract][Full Text] [Related]
5. The prevention of biochemical changes in lens, retina, and nerve of galactosemic dogs by the aldose reductase inhibitor AL01576.
Lou MF; Dickerson JE; Chandler ML; Brazzell RK; York BM
J Ocul Pharmacol; 1989; 5(3):233-40. PubMed ID: 2516529
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting serum protein binding of phenytoin, diazepam and propranolol in acute renal diseases.
Tiula E; Haapanen EJ; Neuvonen PJ
Int J Clin Pharmacol Ther Toxicol; 1987 Sep; 25(9):469-75. PubMed ID: 3679617
[TBL] [Abstract][Full Text] [Related]
7. Determination of AL01576 concentration in rat lenses and plasma by bioassay for aldose reductase activity measurements.
Hockwin O; Müller P; Krolczyk J; McCue BA; Mayer PR
Ophthalmic Res; 1989; 21(4):285-91. PubMed ID: 2511536
[TBL] [Abstract][Full Text] [Related]
8. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors.
Tilton RG; Chang K; Pugliese G; Eades DM; Province MA; Sherman WR; Kilo C; Williamson JR
Diabetes; 1989 Oct; 38(10):1258-70. PubMed ID: 2507378
[TBL] [Abstract][Full Text] [Related]
9. Reduced anterograde and retrograde accumulation of axonally transported phosphofructokinase in streptozotocin-diabetic rats: effects of insulin and the aldose reductase inhibitor 'Statil'.
Willars GB; Calcutt NA; Tomlinson DR
Diabetologia; 1987 Apr; 30(4):239-43. PubMed ID: 2439402
[TBL] [Abstract][Full Text] [Related]
10. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.
Mayer JH; Tomlinson DR
Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336
[TBL] [Abstract][Full Text] [Related]
11. Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
Griffin BW; McNatt LG; Chandler ML; York BM
Metabolism; 1987 May; 36(5):486-90. PubMed ID: 3106757
[TBL] [Abstract][Full Text] [Related]
12. Serum protein binding of phenytoin, diazepam and propranolol in chronic renal diseases.
Tiula E; Tallgren LG; Neuvonen PJ
Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):545-52. PubMed ID: 3429058
[TBL] [Abstract][Full Text] [Related]
13. Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors.
Brazzell RK; Park YH; Wooldridge CB; McCue B; Barker R; Couch R; York B
Drug Metab Dispos; 1990; 18(4):435-40. PubMed ID: 1976064
[TBL] [Abstract][Full Text] [Related]
14. [Aldose reductase inhibitor--a new way for preventing diabetic lens changes?].
Ohrloff C; Hockwin O; Korte I; Wegener A
Klin Monbl Augenheilkd; 1986 Nov; 189(5):361-2. PubMed ID: 3100860
[TBL] [Abstract][Full Text] [Related]
15. Serum protein binding of phenytoin, diazepam and propranolol in age-related decrease in renal function.
Tiula E; Elfving S
Ann Clin Res; 1987; 19(3):163-9. PubMed ID: 3674731
[TBL] [Abstract][Full Text] [Related]
16. Sorbinil suppresses glomerular prostaglandin production in the streptozotocin diabetic rat.
Craven PA; DeRubertis FR
Metabolism; 1989 Jul; 38(7):649-54. PubMed ID: 2500578
[TBL] [Abstract][Full Text] [Related]
17. Treatment with an aldose reductase inhibitor can reduce the susceptibility of fast axonal transport following nerve compression in the streptozotocin-diabetic rat.
Dahlin LB; Archer DR; McLean WG
Diabetologia; 1987 Jun; 30(6):414-8. PubMed ID: 2445613
[TBL] [Abstract][Full Text] [Related]
18. Axonal transport and tissue contents of substance P in rats with long-term streptozotocin-diabetes. Effects of the aldose reductase inhibitor 'statil'.
Robinson JP; Willars GB; Tomlinson DR; Keen P
Brain Res; 1987 Nov; 426(2):339-48. PubMed ID: 2446712
[TBL] [Abstract][Full Text] [Related]
19. The effects of aldose reductase inhibitor on the corneal endothelial morphology in diabetic rats.
Matsuda M; Awata T; Ohashi Y; Inaba M; Fukuda M; Manabe R
Curr Eye Res; 1987 Feb; 6(2):391-7. PubMed ID: 2952464
[TBL] [Abstract][Full Text] [Related]
20. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Kador PF; Kinoshita JH; Sharpless NE
J Med Chem; 1985 Jul; 28(7):841-9. PubMed ID: 3925146
[No Abstract] [Full Text] [Related]
[Next] [New Search]
